Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 4/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933114 | 0.93 | CA1 (0.45) | EPHX2 | |
| SCHEMBL16289859 | 0.83 | EPHX2 (0.58) | TSHRKMT2APKMEPHX2MEN1 | |
| SCHEMBL10290340 | 0.83 | EPHX2 (0.58) | TSHRKMT2APKMEPHX2MEN1 | |
| SCHEMBL16289773 | 0.79 | HDAC3 (0.53) | TSHREPHX2 | |
| SCHEMBL16289210 | 0.79 | SMN1; SMN2 (0.53) | TSHRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15006852 | 0.78 | EPHX2 (0.49) | EPHX2SPHK1TLR2 | |
| SCHEMBL15007033 | 0.78 | EPHX2 (0.49) | EPHX2SPHK1TLR2 | |
| SCHEMBL15006998 | 0.78 | EPHX2 (0.49) | EPHX2SPHK1TLR2 | |
| SCHEMBL19197510 | 0.78 | TSHR (0.64) | TSHRKMT2APKMEPHX2MEN1 | |
| SCHEMBL16216320 | 0.75 | LPL (0.47) | PKMEPHX2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495029-B2 | Prodrugs of (2R)-2-propyloctanoic acid for the treatment of stroke | MERCK & CO., INC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080132488-A1 | Prodrugs of (2R)-2-Propyloctanoic Acid For the Treatment of Stroke | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132488-A1 | Prodrugs of (2R)-2-Propyloctanoic Acid For the Treatment of Stroke | APEH, HCAR2, PTGDR | TSHR 1294/4885KMT2A 2171/4885PKM 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.